Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...
Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback